Prof. Gal Markel

Prof. Gal Markel MD-PhD-MBA


Translational immuno-oncology and reversed personalized medicine.
The objective Prof. Markel’s research group is to define robust, clinically-relevant, biological mechanisms of cancer pathogenesis, and translate the findings into the clinical arena.


  1. Identification of tumor immune evasion mechanisms.
    Delineation of such mechanisms immediately highlights them as potential candidates for novel drug development. Over the years Prof Markel has identified the roles of CEACAM1, ADAR1 and others in immune evasion through multiple mechanisms. Two companies were established based on these findings, cCAM Biotherapeutics that has developed CM-24 (currently being tested in clinical trials) and 4c Biomed that develops a pipeline of novel drugs.
  2. Reversed personalized medicine.
    Altering the patient could lead to re-sensitization to currently available immunotherapy, which offers an exciting approach with quick path into clinical application. Through fecal microbial transplantation, Prof Markel's group has successfully demonstrated this concept in metastatic melanoma patients. Prof Markel's group continues to develop various strategies to alter the patient through dietary strategies and repurposing various off-label drugs.


Contact info:

Prof. Gal Markel MD PhD MBA

Davidoff Cancer Center

Rabin Medical Center

Tel Aviv University makes every effort to respect copyright. If you own copyright to the content contained
here and / or the use of such content is in your opinion infringing, Contact us as soon as possible >>